Stentys completed an initial public offering worth $31.9 million.
The Paris-based cardiac stent developer’s shares are now listed and traded on the NYSE Euronext Paris exchange under the symbol STNT.
Stentys plans to use the proceeds from the IPO to commercialize its stents in Europe and obtain regulatory approvals in the U.S. The company makes a self-apposing stent for treating acute myocardial infarctions, better known as heart attacks.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
“This cash infusion is obviously a very significant event for Stentys, as we now have the means to establish Stentys’ self-apposing stent as the reference treatment for AMI, a $2.3 billion market,” Stentys chairman and co-founder Jacques Seguin said in prepared remarks.
The company recently released positive results from a clinical trial that compared its self-apposing stent with a conventional market-leading stent in patients suffering a heart attack.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
